Immunovant, Inc.

Immunovant, Inc. Earnings Recaps

IMVT Health Care 2 recaps
Next earnings: February 5, 2027 (estimated) · full calendar
Q2 2027 Nov 11, 2026

Roivant’s shares rose 15.1% after the company reported $31 million in initial LISRAYA revenue and said its IMVT-1402 rheumatoid arthritis study met its Period 2 primary endpoint. The positive updates were tempered by management’s decision not to advance the Sjögren’s program, while it cautioned that the launch is early and September-quarter revenue benefited from pharmacy stocking.

Key takeaways
  • LISRAYA generated $31 million in net revenue during five weeks on the market; hundreds of patients were on paid drug at quarter-end, and management said some inventory held by specialty pharmacies had been dispensed after September 30.
  • Management expects pharmacy inventory dynamics to be a modest headwind in the December quarter, but to become irrelevant next year; it said payer policies are still developing and vary in difficulty.
  • IMVT-1402 met the primary endpoint in Period 2 of its RA study, a randomized-withdrawal phase testing maintenance of ACR20 response on 600 mg, 300 mg, or placebo.
  • Roivant said it is unlikely to progress the Sjögren’s program, citing updates in the field; it plans to run the study out and learn from it.
  • Management cited roughly 85,000 U.S. patients with RA who have struggled to get adequately treated, but said it will discuss the commercial opportunity at its December Investor Day.
Q1 2027 Aug 9, 2026

Roivant's stock edged up modestly by 1.7% following a quiet quarter that met expectations without delivering clear catalysts to drive a stronger move. Investors appear to be in a wait-and-see mode ahead of several key data readouts and potential product launches slated for the second half of 2026.

Key takeaways
  • The quarter was described as “quiet,” with no new significant commercial or clinical breakthroughs reported.
  • Brexpiprazole is on track for an imminent launch in dermatomyositis, pending FDA approval, with additional Phase III enrollment advancing in cutaneous sarcoidosis.
  • Several important Phase III data milestones are expected in the second half of 2026 for brexpiprazole in indications including NIU, PH-ILD, and CLE.
  • Progress continues on the Moderna settlement and ongoing litigation against Pfizer and BioNTech.
  • Investors are likely awaiting the upcoming “busier” period in 2H26 and beyond, given the pipeline’s heavy event schedule.